Baili Tianheng announced that the injectable BL-M05D1 (ADC) program for treating locally advanced solid tumors has obtained a Phase I clinical trial approval notice.
百利天恒：注射用BL-M05D1（ADC）项目治疗局部晚期实体瘤获得I期临床试验批准通知书
Baili Tianheng: BL-M05D1 (ADC) for injectable treatment of locally advanced solid tumors obtained approval notice for phase I clinical trials
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.